A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma.
Recent evidence suggests that the vasopressin analogue desglycinamide-arginine8-vasopressin (DGAVP) might specifically benefit mild brain trauma patients. We investigated the effect of intranasal DGAVP treatment in 32 patients who had sustained a mild head injury for 3 months in a double-blind, placebo-controlled, matched-pairs study. DGAVP did not have a positive effect on cognitive recovery in this group of mildly affected patients.
Bohnen
N I
NI
Department of Neuropsychology and Psychobiology, University of Limburg, Maastricht, The Netherlands.
Twijnstra
A
A
Jolles
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology; D006259:Craniocerebral Trauma / Q000150:complications*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D001127:Arginine Vasopressin; C015119:argipressin, des-GlyNH2(9)-